Protocolo diagnóstico y tratamiento de la poliquistosis renal autosómica dominante

  1. Gaitán Tocora, D.G.
  2. del Valle, K.M. Pérez
  3. Hernández Sevillano, B.
  4. Zapata Balcázar, A.P.
  5. de la Fuente, G. de Arriba
Journal:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Year of publication: 2019

Issue Title: Enfermedades nefrourinarias (V)Enfermedades renales tubulointersticiales.Nefropatías hereditarias y congénitas

Series: 12

Issue: 83

Pages: 4906-4908

Type: Article

DOI: HTTPS://DOI.ORG/10.1016/J.MED.2019.06.027 DIALNET GOOGLE SCHOLAR

More publications in: Medicine: Programa de Formación Médica Continuada Acreditado

Abstract

Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common hereditary disorders causing end-stage renal disease (ESRD). Clinical manifestations depend on maturation type of the gene involved (mainly PKD1, PKD2, GNANB y DNAJB11); however, it has been shown that phenotypic expression of the disease can be modified by environmental factors. Since several methods to predict the disease course as well as to determine candidates suitable for treatment are available, early diagnosis is mandatory. Tolvaptan has been reported as the only drug currently available which improves the symptomatology and clinical progression of the disease.

Bibliographic References

  • Ars E, Bernis C, Fraga G, Martínez V, Martins J, Ortiz A. Poliquistosis renal autosómica dominante. Guías clínicas españolas.
  • Chebib FT, Perrone RD, Chapman AB, Dahl NK, Harris PC, Mrug M. A practical guide for treatment of rapidly progressive ADPKD with tolvaptan. J Am Soc Nephrol. 2018;29(10):2458-70.
  • Irazabal M V, Rangel LJ, Bergstralh EJ, Osborn SL, Harmon AJ, Sundsbak JL. Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J Am Soc Nephrol. 2015;26:160-72.
  • Lanktree MB, Chapman AB. New treatment paradigms for ADPKD: Moving towards precision medicine. Nat Rev Nephrol. 2017;13(12):750-68.
  • Müller R-U, Benzing T. Management of autosomal-dominant polycystic kidney disease :state of the art. Clin Kidney J. 2018;11Suppl1:12-3.
  • Pei Y. Diagnostic and therapeutic corner diagnostic approach in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2006;1:1108-14.
  • Torra R, Changzheng S, Mei C-L. Open peer review recent advances in the clinical management of autosomal dominant polycystic kidney disease. [Consultado 12 de abril 2019].
  • Torres VE, Higashihara E, Devuyst O, Chapman AB, Gansevoort RT, Grantham JJ. Effect of tolvaptan in autosomal dominant polycystic kidney disease by CKD stage: Results from the TEMPO 3:4 trial. Clin J Am Soc Nephrol. 2016;11(5):803-11.
Data source: Dialnet